| Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans J Seow, C Graham, B Merrick, S Acors, S Pickering, KJA Steel, ... Nature microbiology 5 (12), 1598-1607, 2020 | 1578 | 2020 |
| A dynamic COVID-19 immune signature includes associations with poor prognosis AG Laing, A Lorenc, I Del Molino Del Barrio, A Das, M Fish, L Monin, ... Nature medicine 26 (10), 1623-1635, 2020 | 985 | 2020 |
| Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study L Monin, AG Laing, M Muñoz-Ruiz, DR McKenzie, IDM Del Barrio, ... The Lancet Oncology 22 (6), 765-778, 2021 | 646 | 2021 |
| Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection MJ Carter, M Fish, A Jennings, KJ Doores, P Wellman, J Seow, S Acors, ... Nature medicine 26 (11), 1701-1707, 2020 | 407 | 2020 |
| The effect of spike mutations on SARS-CoV-2 neutralization C Rees-Spear, L Muir, SA Griffith, J Heaney, Y Aldon, JL Snitselaar, ... Cell reports 34 (12), 108890, 2021 | 239 | 2021 |
| The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study SK Mahil, K Bechman, A Raharja, C Domingo-Vila, D Baudry, MA Brown, ... The Lancet Rheumatology 3 (9), e627-e637, 2021 | 165 | 2021 |
| Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B. 1.1. 7 variant C Graham, J Seow, I Huettner, H Khan, N Kouphou, S Acors, H Winstone, ... Immunity 54 (6), 1276-1289. e6, 2021 | 151* | 2021 |
| Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare … S Pickering, G Betancor, RP Galão, B Merrick, AW Signell, HD Wilson, ... PLoS pathogens 16 (9), e1008817, 2020 | 122 | 2020 |
| SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity A Rosa, VE Pye, C Graham, L Muir, J Seow, KW Ng, NJ Cook, ... SciAdv 7 (22), eabg7607, 2021 | 116 | 2021 |
| Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern L Dupont, LB Snell, C Graham, J Seow, B Merrick, T Lechmere, ... Nature microbiology 6 (11), 1433-1442, 2021 | 110 | 2021 |
| The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate S Gee, M Chandiramani, J Seow, E Pollock, C Modestini, A Das, T Tree, ... Nature immunology 22 (12), 1490-1502, 2021 | 85 | 2021 |
| Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England PM Wells, KJ Doores, S Couvreur, RM Nunez, J Seow, C Graham, ... Journal of Infection 81 (6), 931-936, 2020 | 69 | 2020 |
| Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in … P Harrington, KJ Doores, D Radia, A O’Reilly, HPJ Lam, J Seow, ... British journal of haematology 194 (6), 999-1006, 2021 | 63 | 2021 |
| A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex VA Avanzato, KY Oguntuyo, M Escalera-Zamudio, B Gutierrez, M Golden, ... Proceedings of the National Academy of Sciences 116 (50), 25057-25067, 2019 | 58 | 2019 |
| SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies CA Fielding, P Sabberwal, JC Williamson, EJD Greenwood, TWM Crozier, ... Elife 11, e74489, 2022 | 48* | 2022 |
| Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative … P Harrington, H de Lavallade, KJ Doores, A O’Reilly, J Seow, C Graham, ... Leukemia 35 (12), 3573-3577, 2021 | 46 | 2021 |
| Broad neutralization of SARS-CoV-2 variants, including omicron, following breakthrough infection with Delta in COVID-19-vaccinated individuals T Lechmere, LB Snell, C Graham, J Seow, ZA Shalim, T Charalampous, ... Mbio 13 (2), e03798-21, 2022 | 35 | 2022 |
| Disordered epitopes as peptide vaccines CA MacRaild, J Seow, SC Das, RS Norton Peptide Science 110 (3), e24067, 2018 | 32 | 2018 |
| A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination J Seow, H Khan, A Rosa, V Calvaresi, C Graham, S Pickering, VE Pye, ... Cell Reports 40 (8), 2022 | 31 | 2022 |
| Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer DR McKenzie, M Muñoz-Ruiz, L Monin, T Alaguthurai, T Lechmere, ... Cancer Cell 39 (11), 1445-1447, 2021 | 31 | 2021 |
